Iodixanol

Iodixanol
Systematic (IUPAC) name
5-{N-[3-(N-{3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
Clinical data
AHFS/Drugs.com Multum Consumer Information
Pharmacokinetic data
Protein binding Negligible
Metabolism Excreted unchanged
Biological half-life 2.1 hours
Excretion Renal
Identifiers
CAS Number 92339-11-2 YesY
ATC code V08AB09 (WHO)
PubChem CID 3724
DrugBank DB01249 YesY
ChemSpider 3593 YesY
UNII HW8W27HTXX YesY
KEGG D01474 YesY
ChEBI CHEBI:31705 YesY
ChEMBL CHEMBL1200507 N
Synonyms 5-[acetyl-[3-[acetyl-[3,5-bis(2,3-dihydroxypropylcarbamoyl)-2,4,6-triiodo-phenyl]amino]-2-hydroxy-propyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide
Chemical data
Formula C35H44I6N6O15
Molar mass 1550.191
 NYesY (what is this?)  (verify)

Iodixanol is a contrast agent, sold under the trade name Visipaque; it is also sold as a density gradient medium under the name OptiPrep.[1] Visipaque is commonly used as a contrast agent during coronary angiography. It is the only iso-osmolar contrast agent, with an osmolality of 290 mOsm/kg H2O, the same as blood. It is sold in 2 main concentrations 270 mgI/ml and 320 mgI/ml - hence the name Visipaque 270 or 320. It is sold in single dose units and a large 500ml plastic bottle for multi-dose dispensing

It was originally made by Nycomed, which then merged with Amersham which finally was bought by Jeff Immelt to become GE Healthcare. The majority of Visipaque is made in Cork, Ireland, with additional plants in China and Oslo. All Iodixanol bulk powder is made in Norway and shipped to the various plants for final manufacture.

A very similar product also manufactured by GE Healthcare is Omnipaque (Iohexol as the main drug substance).

References

  1. OptiPrep™: The ideal density gradient medium, Axis-Shield Density Gradient Media. Accessed on line Nov. 19, 2015.

External links

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.